InMed Pharmaceuticals Inc Total Assets
InMed Pharmaceuticals Inc total assets. Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) holds total assets worth $3.03 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see InMed Pharmaceuticals Inc (INM) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of InMed Pharmaceuticals Inc (2001–2026)
Total assets of InMed Pharmaceuticals Inc from 2001 to 2026. This chart illustrates how InMed Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See InMed Pharmaceuticals Inc stock quote for real-time trading data and today's change.
InMed Pharmaceuticals Inc - Asset Composition Analysis
InMed Pharmaceuticals Inc Total Assets Breakdown (June 2026)
InMed Pharmaceuticals Inc total assets breakdown as of June 2026. InMed Pharmaceuticals Inc's total assets of $3.03 Billion consist of 88.3% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2026)
This chart illustrates how InMed Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore InMed Pharmaceuticals Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InMed Pharmaceuticals Inc's current assets represent 88.3% of total assets in 2026, an increase from 50.8% in 2001.
- Cash Position: Cash and equivalents constituted 72.4% of total assets in 2026, up from 0.9% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
InMed Pharmaceuticals Inc Competitors by Total Assets
Key competitors of InMed Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
InMed Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 6.99 | 8.29 |
| Quick Ratio | 1.37 | 6.47 | 8.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $721.65 Million | $15.02 Million | $17.80 Million |
InMed Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between InMed Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 14174.8% |
| Total Assets | $3.03 Billion |
| Market Capitalization | $6.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values InMed Pharmaceuticals Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: InMed Pharmaceuticals Inc's assets grew by 14174.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for InMed Pharmaceuticals Inc (2001–2026)
The table below shows the annual total assets of InMed Pharmaceuticals Inc from 2001 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $3.03 Billion | +14174.78% |
| 2025-06-30 | $21.23 Million | +31.28% |
| 2024-06-30 | $16.17 Million | -13.48% |
| 2023-06-30 | $18.69 Million | +13.50% |
| 2022-06-30 | $16.46 Million | +36.11% |
| 2021-06-30 | $12.10 Million | +55.04% |
| 2020-06-30 | $7.80 Million | -48.24% |
| 2019-06-30 | $15.07 Million | -29.36% |
| 2018-06-30 | $21.34 Million | +232.90% |
| 2017-06-30 | $6.41 Million | +402.07% |
| 2016-06-30 | $1.28 Million | -4.59% |
| 2015-06-30 | $1.34 Million | -15.84% |
| 2014-06-30 | $1.59 Million | +31111.50% |
| 2013-06-30 | $5.09K | -89.23% |
| 2012-06-30 | $47.31K | -80.96% |
| 2011-06-30 | $248.50K | +71.72% |
| 2010-06-30 | $144.72K | +469.27% |
| 2009-06-30 | $25.42K | -98.16% |
| 2008-06-30 | $1.38 Million | +242.49% |
| 2007-06-30 | $403.26K | -38.12% |
| 2006-06-30 | $651.70K | -33.82% |
| 2005-06-30 | $984.74K | +80.39% |
| 2004-06-30 | $545.89K | -53.10% |
| 2003-06-30 | $1.16 Million | -14.61% |
| 2002-06-30 | $1.36 Million | -70.83% |
| 2001-06-30 | $4.67 Million | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more